Efficacy and Safety of IQP-VV-102 in Weight Management

This study has been completed.
Information provided by (Responsible Party):
InQpharm Group
ClinicalTrials.gov Identifier:
First received: September 4, 2012
Last updated: October 5, 2015
Last verified: October 2015
Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored

Condition Intervention Phase
Dietary Supplement: IQP-VV-102
Other: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-VV-102 in Reducing Body Weight in Overweight and Obese Subjects

Resource links provided by NLM:

Further study details as provided by InQpharm Group:

Primary Outcome Measures:
  • Change in Body Weight at End of Study Compared to Baseline [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change in body weight at the end of study compared to baseline

Secondary Outcome Measures:
  • Change in Waist Circumference (in cm) at End of Study From Baseline [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Difference in waist circumference (in cm) at end of study from baseline

  • Change in Mean Body Fat at End of Study From Baseline [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Measured in kg using calibrated weighing scales

Enrollment: 120
Study Start Date: October 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: IQP-VV-102
2 tablets twice a day
Dietary Supplement: IQP-VV-102
Placebo Comparator: Placebo
2 tablets twice a day
Other: Placebo


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18 to 60 years
  • 25 kg/m2 ≤ BMI ≤ 35 kg/m2
  • Written informed consent

Exclusion Criteria:

  • Known sensitivity to sources of the active ingredients and excipients
  • Pregnancy or nursing
  • Inability to comply with study requirements, e.g. due to language difficulties
  • Participation in another study during the last 30 days of the screening visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01681069

Barbara Grube
Berlin, Germany, 10709
Sponsors and Collaborators
InQpharm Group
Principal Investigator: Barbara Grube, MD Practice for General Medicine
  More Information

No publications provided

Responsible Party: InQpharm Group
ClinicalTrials.gov Identifier: NCT01681069     History of Changes
Other Study ID Numbers: INQ/009712
Study First Received: September 4, 2012
Results First Received: September 1, 2015
Last Updated: October 5, 2015
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on November 27, 2015